0 901

Cited 115 times in

Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.

 Yoon Jin Cha  ;  Hye Ryun Kim  ;  Chang Young Lee  ;  Byoung Chul Cho  ;  Hyo Sup Shim 
 LUNG CANCER, Vol.97 : 73-80, 2016 
Journal Title
Issue Date
Adenocarcinoma/metabolism* ; Adenocarcinoma/mortality ; Adenocarcinoma/pathology* ; Adenocarcinoma/surgery ; Adult ; Aged ; Aged, 80 and over ; B7-H1 Antigen/metabolism* ; Biomarkers, Tumor/metabolism ; Disease-Free Survival ; Female ; Genes, erbB-1/genetics ; Genes, p53/immunology* ; Humans ; Immunotherapy ; Lung Neoplasms/metabolism* ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology* ; Lung Neoplasms/surgery ; Lymphocytes, Tumor-Infiltrating/metabolism ; Male ; Middle Aged ; Molecular Targeted Therapy ; Mutation ; Neoplasm Staging ; Prognosis ; Protein-Tyrosine Kinases/genetics ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins p21(ras)/genetics ; Receptor Protein-Tyrosine Kinases/genetics ; Retrospective Studies ; Smoking/epidemiology
Adenocarcinoma ; Cancer immunotherapy ; Lung cancer ; PD-L1 ; p53
INTRODUCTION: PD-L1 expression is a predictive biomarker for response to anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors and can be evaluated by immunohistochemistry. Results of the clinicopathologic characteristics of PD-L1-positive lung adenocarcinoma have been inconsistent in previous studies, and there are no reports on the relationship between PD-L1 expression and p53 status in lung adenocarcinoma.
METHODS: We examined PD-L1 and p53 expression in a total of 323 surgically resected lung adenocarcinoma cases using anti-PD-L1 (clone SP142) and anti-p53 (clone DO-7) antibodies, and analyzed the clinicopathologic characteristics of PD-L1-positive cases and their relationship with p53 status.
RESULTS: PD-L1 expression in tumor cells was positive in 60 of 323 cases (18.6%). Higher PD-L1 expression (≥50%) was more prevalent in former or current smokers (p=0.026) and was associated with more pack-years (p=0.016). PD-L1-positive tumors were significantly associated with solid predominant type (p<0.001), p53 aberrant expression (p<0.001), and PD-L1 expression in tumor-infiltrating immune cells (p<0.001). Patients with stage I to III tumors harboring PD-L1-positive tumor cells showed poor recurrence-free survival (p<0.001) and overall survival (p<0.001) on univariate analysis.
CONCLUSIONS: PD-L1 expression in tumor cells, solid predominant histology, p53 aberrant expression, and PD-L1 expression in tumor-infiltrating immune cells are closely related. These variables should be considered when analyzing the clinical outcomes of patients with lung adenocarcinomas treated with anti-PD1/PD-L1 immune checkpoint inhibitors.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Hye Ryun(김혜련) ORCID logo https://orcid.org/0000-0002-1842-9070
Shim, Hyo Sup(심효섭) ORCID logo https://orcid.org/0000-0002-5718-3624
Lee, Chang Young(이창영)
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
Cha, Yoon Jin(차윤진) ORCID logo https://orcid.org/0000-0002-5967-4064
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.